173 related articles for article (PubMed ID: 34940080)
21. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
[No Abstract] [Full Text] [Related]
22. Liquid biopsy assay for lung carcinoma using centrifuged supernatants from fine-needle aspiration specimens.
Hannigan B; Ye W; Mehrotra M; Lam V; Bolivar A; Zalles S; Barkoh BA; Duose D; Hu PC; Broaddus R; Stewart J; Heymach J; Medeiros LJ; Wistuba I; Luthra R; Roy-Chowdhuri S
Ann Oncol; 2019 Jun; 30(6):963-969. PubMed ID: 30887015
[TBL] [Abstract][Full Text] [Related]
23. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive characterization reveals sputum supernatant as a valuable alternative liquid biopsy for genome profiling in advanced non-small cell lung cancer.
Xie X; Wu J; Guo B; Wang L; Deng H; Lin X; Liu M; Qin Y; Luo W; Yang Y; Zou X; Hou T; Xiang J; Chen Z; Zhou C
Respir Res; 2022 Jul; 23(1):175. PubMed ID: 35778703
[TBL] [Abstract][Full Text] [Related]
25. Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC.
Schwartzberg LS; Li G; Tolba K; Bourla AB; Schulze K; Gadgil R; Fine A; Lofgren KT; Graf RP; Oxnard GR; Daniel D
JTO Clin Res Rep; 2022 Sep; 3(9):100386. PubMed ID: 36089920
[TBL] [Abstract][Full Text] [Related]
26. Hybrid Capture-Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Non-Small Cell Lung Cancer.
Schrock AB; Welsh A; Chung JH; Pavlick D; Bernicker EH; Creelan BC; Forcier B; Ross JS; Stephens PJ; Ali SM; Dagogo-Jack I; Shaw AT; Li T; Ou SI; Miller VA
J Thorac Oncol; 2019 Feb; 14(2):255-264. PubMed ID: 30368012
[TBL] [Abstract][Full Text] [Related]
27. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
Moldaver D; Hurry M; Evans WK; Cheema PK; Sangha R; Burkes R; Melosky B; Tran D; Boehm D; Venkatesh J; Walisser S; Orava E; Grima D
Lung Cancer; 2020 Jan; 139():185-194. PubMed ID: 31812889
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
29. Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.
Kasi PM; Lee JK; Pasquina LW; Decker B; Vanden Borre P; Pavlick DC; Allen JM; Parachoniak C; Quintanilha JCF; Graf RP; Schrock AB; Oxnard GR; Lovly CM; Tukachinsky H; Subbiah V
Clin Cancer Res; 2024 Feb; 30(4):836-848. PubMed ID: 38060240
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing.
Doble B; John T; Thomas D; Fellowes A; Fox S; Lorgelly P
Lung Cancer; 2017 May; 107():22-35. PubMed ID: 27316470
[TBL] [Abstract][Full Text] [Related]
32. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples.
Tomlins SA; Hovelson DH; Suga JM; Anderson DM; Koh HA; Dees EC; McNulty B; Burkard ME; Guarino M; Khatri J; Safa MM; Matrana MR; Yang ES; Menter AR; Parsons BM; Slim JN; Thompson MA; Hwang L; Edenfield WJ; Nair S; Onitilo A; Siegel R; Miller A; Wassenaar T; Irvin WJ; Schulz W; Padmanabhan A; Harish V; Gonzalez A; Mansoor AH; Kellum A; Harms P; Drewery S; Falkner J; Fischer A; Hipp J; Kwiatkowski K; Lazo de la Vega L; Mitchell K; Reeder T; Siddiqui J; Vakil H; Johnson DB; Rhodes DR
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476329
[TBL] [Abstract][Full Text] [Related]
33. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH
Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540
[TBL] [Abstract][Full Text] [Related]
34. Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer.
Steuten L; Goulart B; Meropol NJ; Pritchard D; Ramsey SD
JCO Clin Cancer Inform; 2019 Jun; 3():1-10. PubMed ID: 31242043
[TBL] [Abstract][Full Text] [Related]
35. Urine circulating-tumor DNA (ctDNA) detection of acquired EGFR T790M mutation in non-small-cell lung cancer: An outcomes and total cost-of-care analysis.
Sands J; Li Q; Hornberger J
Lung Cancer; 2017 Aug; 110():19-25. PubMed ID: 28676213
[TBL] [Abstract][Full Text] [Related]
36. Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma.
Raman L; Van der Linden M; Van der Eecken K; Vermaelen K; Demedts I; Surmont V; Himpe U; Dedeurwaerdere F; Ferdinande L; Lievens Y; Claes K; Menten B; Van Dorpe J
Genome Med; 2020 Apr; 12(1):35. PubMed ID: 32317009
[TBL] [Abstract][Full Text] [Related]
37. Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy.
Yoshii Y; Okazaki S; Takeda M
Life (Basel); 2021 Aug; 11(8):. PubMed ID: 34440540
[TBL] [Abstract][Full Text] [Related]
38. Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative.
Lim SM; Kim EY; Kim HR; Ali SM; Greenbowe JR; Shim HS; Chang H; Lim S; Paik S; Cho BC
Oncotarget; 2016 Apr; 7(17):24172-8. PubMed ID: 26992220
[TBL] [Abstract][Full Text] [Related]
39. Method of Tissue Acquisition Affects Success of Comprehensive Genomic Profiling in Lung Cancer.
Mata DA; Harries L; Williams EA; Hiemenz MC; Decker B; Tse JY; Janovitz T; Ferguson DC; Speece IA; Margolis ML; Mathews B; Fedorchak K; Killian JK; Xiao J; Tolba KA; Ramkissoon S; Vergilio JA; Elvin JA; Oxnard GR; Ross JS; Huang RSP
Arch Pathol Lab Med; 2023 Mar; 147(3):338-347. PubMed ID: 35771716
[TBL] [Abstract][Full Text] [Related]
40. EGFR mutation testing from liquid biopsy of non-small cell lung cancer at the Institute for Oncology and Radiology of Serbia.
Cavic M; Krivokuca A; Pavlovic M; Boljevic I; Rakobradovic J; Mihajlovic M; Tanic M; Damjanovic A; Malisic E; Jankovic R
J BUON; 2020; 25(6):2635-2642. PubMed ID: 33455107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
